32 / 36
IMMUNE GENE EXPRESSION
SIGNATURES WERE STRONGLY
PROGNOSTIC FOR RFS
Factor
HR
Lower
Upper
P
Value
(Baseline)
a
(1)
–
–
–
IIIB
1.63
0.94
2.84
0.076
IIIC
1.89
1.07
3.36
Ulceration
1.13
0.80
1.59
0.488
IFN-γ
0.76
0.67
0.86
< 0.001
Factor
HR
Lower
Upper
P
Value
(Baseline)
a
(1)
–
–
–
IIIB
1.31
0.67
2.55
0.045
IIIC
2.04
1.05
3.96
Ulceration
0.99
0.64
1.53
0.952
IFN-γ
0.61
0.52
0.73
< 0.001
Placebo
Dabrafenib + Trametinib
Multivariate Cox analysis.
a
Stage IIIA, no ulceration, INF-γ = 0.
PRESENTED BY GV LONG AT ESMO 2018
IFN, interferon; PBO, placebo.
0
0
20
40
60
80
100
8
20 28 36
52 60
134 72
44
40
35
9
1
120 107
71
58
51
131 124
105 96
92
17
6
122 88
4
89
118
127
104
12
57
99
114
76
66
61
57
44
27
25
63
40
7
42
39
31
1
64
52
39
99
94
72
5 1
1
53
89
110
70
62
59
51
20
14
37
20
2
D+T, low IFN-
γ
D+T , high IFN-
γ
PBO, low IFN-
γ
PBO, high IFN-
γ
Months
D+T, low IFN-
γ
D+T , high IFN-
γ
PBO, low IFN-
γ
PBO, high IFN-
γ
RFS, %
16 24 32 40 48 56
0
0
No. at risk
SLIDES ARE THE PROPERTY OF THE AUTHOR. PERMISSION REQUIRED FOR REUSE.